Germline editing is ethically justifiable – can solve economic equality concerns with enhanced access.
DANIEL J. MALKIN attorney practicing in intellectual property law. 2021 GERMLINE EDITING USING CRISPR: WHY A MORATORIUM IS NOT THE SOLUTION, 55 Fam. L.Q. 69
Using CRISPR to repair germline mutations that cause serious congenital single-gene diseases is ethically justifiable. Such a use poses even fewer ethical barriers than does IVF generally, which is minimally regulated. Therefore, the COA erred in forbidding the FDA to even consider clinical germline editing applications.
For certain applications, modifying severe single-gene diseases in the germline using CRISPR would satisfy the FDA's benefit-risk analysis. For example, where both parents will pass on the Huntington's disease mutation to their children, CRISPR may be the only potential treatment to eliminate the mutation. Evidence also shows that public opinion strongly supports such use for CRISPR to address serious medical conditions or diseases. While equal access to the therapy poses an ethical concern, the answer is to enhance access, rather than to reject treatments that could eliminate serious physical or mental impairments that would substantially limit a child's major life activities. Finally, fears of a new eugenics movement should be allayed if the FDA authorizes germline editing licenses only for therapies targeting severe single-gene diseases.